Alpha-Lipoic Acid
Also known as: ALA, thioctic acid, alpha lipoic acid
Randomised trials and meta-analyses report that oral ALA can reduce sensory symptom scores in diabetic sensorimotor peripheral neuropathy with a dose-related trend (studies using 600–1800 mg/day). However, a Cochrane review of longer (≥6 month) trials concluded ALA probably has little or no effect on neuropathy symptoms at six months and judged included trials at high risk of bias. Systematic reviews in other conditions (for example burning mouth syndrome) found low pooled effects on pain scores but some increased positive effect on longer-term assessment.
Last reviewed: 2026-10-14 · 4 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Alpha-lipoic acid (ALA) is an antioxidant compound sold as a dietary supplement and used orally for conditions such as diabetic neuropathy and some chronic pain syndromes. Clinical evidence is mixed: some meta-analyses report small-to-moderate symptom improvements in diabetic sensorimotor peripheral neuropathy, while other systematic reviews find little or no effect on neuropathy symptoms in longer trials.
Mechanism & Function
Mechanism of Action
Reported mechanisms in the included abstracts are antioxidant activity, reduction of oxidative stress and improvement of microcirculation, which may reduce sensory symptoms in peripheral neuropathy.
Physiological Role
Acts as an antioxidant and redox modulator; implicated in cellular defence against oxidative damage and in microvascular function.
Primary Pathways
Performance / Health Relevance
Not primarily an ergogenic agent. Any performance or recovery benefits would be indirect via reduction of neuropathic symptoms or systemic oxidative stress; the clinical literature provided focuses on symptom relief in neuropathy and certain pain syndromes rather than athletic performance.
Evidence Review
Practical Use & Dosage
- Minimum Effective Dose
- 600 mg/day (reported in trials)
- Optimal Range
- 600–1800 mg/day (dose-related effects reported in meta-analysis for neuropathy)
- Upper / Caution Level
- Not established from these abstracts; trials included up to 1800 mg/day
- Timing
- Oral, daily
- Best Format
- Oral capsules or tablets
- Bioavailability
- Not reported in the provided abstracts.
- Absorption Considerations
- Not reported in the provided abstracts.
Safety & Interactions
Side Effects
- •Adverse events reported in trials (details not specified in provided abstracts)
Contraindications
- Not specified in the provided abstracts
Drug Interactions
- •Not specified in the provided abstracts
Who Should Avoid
- •Not specified in the provided abstracts
Monitoring
Trials reported adverse events and attrition; longer trials were judged at high risk of bias due to attrition in one review. Clinicians and individuals should monitor for tolerability in longer courses.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is Alpha-Lipoic Acid typically used or indicated?
Alpha-Lipoic Acid is most commonly used for: Diabetic peripheral neuropathy / neuropathic pain, General antioxidant support, Support for metabolic and cardiovascular risk factors, Adjunct for idiopathic pain syndromes (e.g. burning mouth syndrome). Acts as an antioxidant and redox modulator; implicated in cellular defence against oxidative damage and in microvascular function.
How does Alpha-Lipoic Acid work?
Reported mechanisms in the included abstracts are antioxidant activity, reduction of oxidative stress and improvement of microcirculation, which may reduce sensory symptoms in peripheral neuropathy.
What is the recommended dose of Alpha-Lipoic Acid?
The optimal range is 600–1800 mg/day (dose-related effects reported in meta-analysis for neuropathy). with a minimum effective dose of 600 mg/day (reported in trials). Best taken: Oral, daily. Upper / caution level: Not established from these abstracts; trials included up to 1800 mg/day.
What are the side effects of Alpha-Lipoic Acid?
Reported side effects include: Adverse events reported in trials (details not specified in provided abstracts). Monitoring: Trials reported adverse events and attrition; longer trials were judged at high risk of bias due to attrition in one review. Clinicians and individuals should monitor for tolerability in longer courses.
Does Alpha-Lipoic Acid interact with medications?
Known or theoretical interactions: Not specified in the provided abstracts. Always check with a clinician before combining with prescription medication.
Who should avoid Alpha-Lipoic Acid?
Alpha-Lipoic Acid is generally not recommended for: Not specified in the provided abstracts; and Not specified in the provided abstracts.
How strong is the evidence for Alpha-Lipoic Acid?
Evidence level: Moderate (overall score 59/100), based on 4 indexed studies on SuppIndex.
Research & References (4)
A systematic review of treatment for patients with burning mouth syndrome.
Systematic review of treatments for burning mouth syndrome that included phytomedicines and alpha-lipoic acid supplements. Pooled effect of ALA on pain score improvement was low, but positive effects increased in longer-term assessment.
Alpha-lipoic acid for diabetic peripheral neuropathy.
Cochrane systematic review of oral ALA versus placebo for diabetic peripheral neuropathy including randomised trials of at least six months' duration. Incorporated three trials (816 participants).
Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review.
Meta-analysis of oral ALA versus placebo in diabetic sensorimotor peripheral neuropathy (10 RCTs, 1242 patients). Primary outcome TSS with subgroup analysis by dose (600, 1200, 1800 mg/day).
Micronutrient Supplementation to Reduce Cardiovascular Risk.
Large systematic review and meta-analysis of micronutrient supplementation on cardiovascular risk factors and events. ALA was among supplements reported to show moderate- to high-quality evidence for reducing some cardiovascular risk factors.
Related Ingredients
Other top-rated ingredients in General Health Ingredients.
Piperine
82/100A piperidine alkaloid (C₁₇H₁₉NO₃) that inhibits cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2E1), P-glycoprotein efflux transporters, and UDP-glucuronosyltransferases while enhancing intestinal permeability, digestive enzyme secretion, and splanchnic blood flow — collectively producing dramatic improvements in nutrient bioavailability.
CoQ10
78/100Endogenous lipid-soluble ubiquinone/ubiquinol that shuttles electrons in the mitochondrial respiratory chain and acts as a membrane antioxidant.
Beta-Glucan (Oat)
77/100Multiple randomized trials and meta-analyses report that ≥3 g/day oat beta-glucan lowers LDL and total cholesterol modestly. Acute feeding trials pooled in meta-analysis show dose- and molecular-weight–dependent reductions in postprandial glucose and insulin responses.
Research Overview
Moderate EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/alpha-lipoic-acid
SuppIndex. (2026). Alpha-Lipoic Acid: Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/alpha-lipoic-acid
Based on 4 indexed studies · Evidence level: Moderate.
Goal Ratings
Stack Compatibility
No specific incompatibilities reported in the provided abstracts.